Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Julio RosenstockYehuda HandelsmanJosep VidalF Javier Ampudia BlascoFrancesco GiorginoMinzhi LiuRiccardo PerfettiJuris J MeierPublished in: Diabetes, obesity & metabolism (2018)
Indirect propensity-score-matched exploratory comparisons suggest that early treatment with a simultaneous, titratable, fixed-ratio combination of basal insulin and a GLP-1RA (iGlarLixi) may be more effective and possess better gastrointestinal tolerability than a sequential approach of adding a GLP-1RA in patients with uncontrolled T2D initiating or intensifying basal insulin therapy.
Keyphrases
- type diabetes
- glycemic control
- rheumatoid arthritis
- insulin resistance
- cardiovascular disease
- disease activity
- randomized controlled trial
- ankylosing spondylitis
- metabolic syndrome
- adipose tissue
- skeletal muscle
- open label
- combination therapy
- smoking cessation
- mesenchymal stem cells
- systemic lupus erythematosus
- cell therapy
- idiopathic pulmonary fibrosis